Related Experiment Video
Updated: Jul 8, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Microalbuminuria is not associated with cisplatin-induced azotemia in dogs
Karoliina Autio1, Kenneth M Rassnick, Richard E Goldstein
1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Background:
Cisplatin is an effective antineoplastic agent but its use is limited by renal toxicity. Microalbuminuria is a marker of renal damage and might be an indicator of cisplatin-induced azotemia.
Null Hypothesis:
Microalbuminuria is not associated with azotemia in dogs treated with cisplatin.
Animals:
This study used 32 client-owned dogs.
Methods:
This was a prospective observational study in which cancer-bearing dogs were treated with cisplatin chemotherapy. Cisplatin-induced azotemia was defined as an increase of serum creatinine concentration above the reference range. Serum creatinine concentration, other routine tests of renal function, and microalbuminuria were measured after each cisplatin treatment. Variables potentially associated with azotemia were compared by use of Fisher's exact test and Wilcoxon's rank-sum test.
Results:
Cisplatin-induced azotemia occurred in 10 (31%) dogs after 1-5 treatments. At each of the first 3 treatments, the proportions of dogs with microalbuminuria were similar between dogs with and without azotemia.
Conclusions And Clinical Importance:
Microalbuminuria measured after each treatment was not associated with azotemia through the first 3 treatments. Testing for microalbuminuria as a marker for cisplatin-induced renal damage is insensitive and not recommended.
Insights
Microalbuminuria does not reliably predict cisplatin-induced kidney damage (azotemia) in dogs. This study found no association between microalbuminuria and azotemia in dogs receiving cisplatin chemotherapy.
Area of Science:
- Veterinary Oncology
- Nephrology
- Pharmacology
Background:
- Cisplatin is a vital chemotherapy drug for various cancers.
- Renal toxicity is a significant limitation to cisplatin therapy.
- Microalbuminuria is a potential indicator of kidney damage.
Purpose of the Study:
- To investigate the association between microalbuminuria and cisplatin-induced azotemia in dogs.
- To determine if microalbuminuria can serve as a predictive marker for kidney damage in dogs treated with cisplatin.
Main Methods:
- Prospective observational study involving 32 client-owned dogs treated with cisplatin.
- Azotemia defined as elevated serum creatinine post-cisplatin treatment.
- Microalbuminuria and renal function tests monitored after each treatment.
Main Results:
- Cisplatin-induced azotemia developed in 31% of dogs.
- No significant difference in microalbuminuria prevalence between dogs with and without azotemia after the first three treatments.
- Microalbuminuria was not found to be associated with azotemia.
Conclusions:
- Microalbuminuria is an insensitive marker for detecting cisplatin-induced renal damage in dogs.
- Routine testing for microalbuminuria is not recommended for monitoring cisplatin nephrotoxicity.
- Further research may explore alternative biomarkers for early detection of kidney injury.
Related Concept Videos
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies I: Urinalysis

